Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a…

By M. Nauck, G. Meininger, D. Sheng, L. Terranella, P. Stein. Diabetes, obesity and metabolism, 2007

674 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. (2007, background): “There were no consistent changes in lipid profile with either sitagliptin(20,22-25) or vildagliptin(28-35,37,38) compared with placebo, but there were some improvements in triglycerides(20,23,24,35) and low- and high-density lipoprotein cholesterol.(20,23,25,37) Relative to rosiglitazone, vildaglipt”
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, methodology): “Antiexenatide antibodies were detected in 41 to 49% of patients in the treatment arms but were not associated with loss of glycemic control (Buse et al., 2004; DeFronzo et al., 2005; Heine et al., 2005; Kendall et al., 2005; Nauck et al., 2007a; Zinman et al., 2007).”
Update on the treatment of type 2 diabetes mellitus. (2016, background): “Some, but not all, studies have reported a slight increased risk of gastrointestinal side effects with sitagliptin [108,109,126] .”